SIFI SpA
Catania, Italy, April 20 /PRNewswire/
SIFI, a leading pharmaceutical company in the development of innovative solutions for the treatment of eye diseases, presented at the ARVO Annual Meeting in New Orleans a number of scientific posters supporting preclinical and clinical research on its innovative product pipeline.
Among other things, the results of preclinical and clinical studies on XanterDES, a novel ophthalmic lubrication solution intended to alleviate eye problems in patients with dry eyes, were presented.
“Dry eye is still a challenge that affects millions of people worldwide. SIFI is fully committed to finding innovative solutions to treat and manage this disease,” stated Maria Cristina Curatolo, SIFI Innovation and Medical Science Director. “XanterDES represents a major innovation in dry eye treatment due to its unique formulation and we are pleased to have presented preclinical and clinical posters of this novel eye drop.”
Below is a list of titles and authors:
- XanterDES “New eye drop formulation based on desonide and xanthan gum: preclinical study” (Zappulla C, La Rosa LR, De Pasquale G, Santonocito M, Spina D, Abbate I, Curatolo MC, Mazzone MG, Viola S)
Presentation number — Posterboard number: 672 — B0343
Session Title: Dry Eye
- XanterDES “Multi-center clinical study on the use of a preservative-free ophthalmic solution based on 0.2% xanthan gum and 0.025% desonide sodium phosphate for the treatment of ocular symptoms in dry eye patients” (Giannaccare G, Gagliano C, Civiale C, Aragona P)
Presentation number – Posterboard number: 3957 – B0274
Session Title: Dry Eye (Clinical)
- XanterDES “Efficacy and safety of a novel ophthalmic solution containing 0.2% xanthan gum and 0.025% desonide sodium phosphate for the treatment of dry eye” (Rossi C., Bifezzi L., Carnovale Scalzo G., Scorcia V., Giannaccare G.)
Session Title: Dry Eye (Clinical)
XanterDES is an ophthalmic lubricating solution designed to relieve discomfort and eye irritation caused by environmental factors such as dust, heat, smoke, wind, air conditioning and allergens. XanterDES is part of SIFI’s well-known dry eye therapeutic portfolio. XanterDES is already available in Italy and Romania and will soon be available in other markets.
SIFI is a leading international ophthalmology company headquartered in Italy, focused on ophthalmology since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients suffering from eye diseases. SIFI is committed to improving the quality of life of patients through its research and development, exporting treatments to more than 40 countries worldwide, with a direct presence in Italy, Spain, France, Romania, Mexico and Turkey.
Contact:
[email protected] , +39 3336999669
View original content:
Original content by: SIFI SpA, transmitted by news aktuell
